Exelixis, Inc.
General ticker "EXEL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $11.3B (TTM average)
Exelixis, Inc. follows the US Stock Market performance with the rate: 55.9%.
Estimated limits based on current volatility of 2.4%: low 54.94$, high 57.68$
Factors to consider:
- Total employees count: 1147 (-12.4%) as of 2025
- US accounted for 84.1% of revenue in the fiscal year ended 2025-01-03
- Top business risk factors: Commercial success risk, Sales capability maintenance, Reimbursement risks, Pipeline development failure, Labor/talent shortage/retention
- Current price 10.2% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2026-01-02 to 2028-01-02
- 2026-01-02 to 2027-01-02 estimated range: [35.82$, 53.13$]
- 2027-01-02 to 2028-01-02 estimated range: [38.54$, 56.71$]
Financial Metrics affecting the EXEL estimates:
- Negative: with PPE of 14.6 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 37.59 > 18.77
- Positive: 6.77 < Operating cash flow per share per price, % of 7.21
- Positive: Return on assets ratio (scaled to [-100,100]) of 21.58 > 6.06
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Inventory ratio change, % of -0.10 <= 0
- Positive: Shareholder equity ratio, % of 75.98 > 63.63
Short-term EXEL quotes
Long-term EXEL plot with estimates
Financial data
| YTD | 2023-12-31 | 2025-01-03 | 2026-01-02 |
|---|---|---|---|
| Operating Revenue | $1,830.21MM | $2,168.70MM | $2,320.13MM |
| Operating Expenses | $1,659.32MM | $1,564.08MM | $1,447.93MM |
| Operating Income | $170.88MM | $604.62MM | $872.19MM |
| Non-Operating Income | $86.64MM | $77.02MM | $69.02MM |
| R&D Expense | $1,044.07MM | $910.41MM | $825.00MM |
| Income(Loss) | $257.52MM | $681.64MM | $941.21MM |
| Taxes | $49.76MM | $160.37MM | $158.64MM |
| Net Income(Loss)* | $207.76MM | $521.27MM | $782.57MM |
| Stockholders Equity | $2,263.91MM | $2,244.20MM | $2,161.32MM |
| Inventory | $17.32MM | $22.39MM | $21.69MM |
| Assets | $2,942.36MM | $2,947.69MM | $2,844.42MM |
| Operating Cash Flow | $333.32MM | $699.97MM | $884.27MM |
| Capital expenditure | $162.97MM | $66.19MM | $39.93MM |
| Investing Cash Flow | $-26.95MM | $-116.78MM | $350.44MM |
| Financing Cash Flow | $-546.05MM | $-628.81MM | $-969.59MM |
| Earnings Per Share** | $0.65 | $1.80 | $2.88 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.